Announcement on Expected Loss in Performance for 2025
Filed with SSE · · 2 pages · Chinese
Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. on 6ix
Earlier from Beijing Wantai Biological Pharmacy Enterprise
- Announcement on the Periodic Qualification (PQ) by WHO of the Bivalent HPV Vaccine
- Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License for Wholly-owned Subsidiary
- Announcement on Resolutions of the 14th Meeting of the 6th Board of Directors
- Announcement on Acceptance of Clinical Trial Application for Recombinant Trivalent Rotavirus Subunit Vaccine (Escherichia coli)
- Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License
Later from Beijing Wantai Biological Pharmacy Enterprise
- Announcement on Plan of Shareholding Reduction by Directors through Call Auction
- Announcement on Approval for Clinical Trials of the Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
- Announcement on Redemption at Maturity of Some Idle Raised Funds Used for Cash Management and Continuing Cash Management
- Announcement on Resignation of Secretary of Board of Directors
- Announcement on Approval Notice of Clinical Trial for Recombinant Trivalent Rotavirus Subunit Vaccine (Escherichia coli)
Follow Beijing Wantai Biological Pharmacy Enterprise into a list and get an email when it puts out news.
Follow Beijing Wantai Biological Pharmacy Enterprise